MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 31, 2005; DOI: 10.1124/mol.105.015727


0026-895X/05/6806-1524-1533$20.00
Mol Pharmacol 68:1524-1533, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.015727v1
68/6/1524    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavva, N. R.
Right arrow Articles by Treanor, J. J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavva, N. R.
Right arrow Articles by Treanor, J. J. S.

Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1{boxs}

Narender R. Gavva, Rami Tamir, Lana Klionsky, Mark H. Norman, Jean-Claude Louis, Kenneth D. Wild, and James J. S. Treanor

Departments of Neuroscience (N.R.G., R.T., L.K., J.-C.L., K.D.W., J.J.S.T.) and Chemistry Research & Discovery (M.H.N.), Amgen Inc., Thousand Oaks, California

Vanilloid receptor 1 (TRPV1) is activated by chemical ligands (e.g., capsaicin and protons) and heat. In this study, we show that (2E)-3-[2-piperidin-1-yl-6-(trifluoromethyl)pyridin-3-yl]-N-quinolin-7-ylacrylamide (AMG6880), 5-chloro-6-{(3R)-3-methyl-4-[6-(trifluoromethyl)-4-(3,4,5-trifluorophenyl)-1H-benzimidazol-2-yl]piperazin-1-yl}pyridin-3-yl)methanol (AMG7472), and N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC) are potent antagonists of rat TRPV1 activation by either capsaicin or protons (pH 5) (defined here as group A antagonists), whereas (2E)-3-(6-tert-butyl-2-methylpyridin-3-yl)-N-(1H-indol-6-yl)acrylamide (AMG0610), capsazepine, and (2E)-3-(4-chlorophenyl)-N-(3-methoxyphenyl)acrylamide (SB-366791) are antagonists of capsaicin, but not proton, activation (defined here as group B antagonists). By using capsaicin-sensitive and insensitive rabbit TRPV1 channels, we show that antagonists require the same critical molecular determinants located in the transmembrane domain 3/4 region to block both capsaicin and proton activation, suggesting the presence of a single binding pocket. To determine whether the differential pharmacology is a result of proton activation-induced conformational changes in the capsaicin-binding pocket that alter group B antagonist affinities, we have developed a functional antagonist competition assay. We hypothesized that if group B antagonists bind at the same or an overlapping binding pocket of TRPV1 as group A antagonists, and proton activation does not alter the binding pocket, then group B antagonists should compete with and prevent group A antagonism of TRPV1 activation by protons. Indeed, we found that each of the group B antagonists competed with and prevented BCTC, AMG6880 or AMG7472 antagonism of rat TRPV1 activation by protons with pA2 values similar to those for blocking capsaicin, indicating that proton activation does not alter the conformation of the TRPV1 capsaicin-binding pocket. In conclusion, group A antagonists seem to lock the channel conformation in the closed state, blocking both capsaicin and proton activation.


Received June 14, 2005; accepted August 30, 2005

Address correspondence to: Dr. Narender R. Gavva, Department of Neuroscience, Amgen Inc., MS-29-2-B, One Amgen Center Dr., Thousand Oaks, CA 91320-1799. E-mail: ngavva{at}amgen.com




This article has been cited by other articles:


Home page
J. Neurosci.Home page
B. Xiao, A. E. Dubin, B. Bursulaya, V. Viswanath, T. J. Jegla, and A. Patapoutian
Identification of Transmembrane Domain 5 as a Critical Molecular Determinant of Menthol Sensitivity in Mammalian TRPA1 Channels
J. Neurosci., September 24, 2008; 28(39): 9640 - 9651.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. S. Surowy, T. R. Neelands, B. R. Bianchi, S. McGaraughty, R. El Kouhen, P. Han, K. L. Chu, H. A. McDonald, M. Vos, W. Niforatos, et al.
(R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 879 - 888.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. G. Lehto, R. Tamir, H. Deng, L. Klionsky, R. Kuang, A. Le, D. Lee, J.-C. Louis, E. Magal, B. H. Manning, et al.
Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 218 - 229.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
P. M. Blumberg
Lighting a Backfire to Quench the Blaze: A Combined Drug Approach Targeting the Vanilloid Receptor TRPV1
Mol. Interv., December 1, 2007; 7(6): 310 - 312.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. A. Matta and G. P. Ahern
Voltage is a partial activator of rat thermosensitive TRP channels
J. Physiol., December 1, 2007; 585(2): 469 - 482.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Semtner, M. Schaefer, O. Pinkenburg, and T. D. Plant
Potentiation of TRPC5 by Protons
J. Biol. Chem., November 16, 2007; 282(46): 33868 - 33878.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. R. Gavva, A. W. Bannon, D. N. Hovland Jr., S. G. Lehto, L. Klionsky, S. Surapaneni, D. C. Immke, C. Henley, L. Arik, A. Bak, et al.
Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al.
Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
N. R. Gavva, A. W. Bannon, S. Surapaneni, D. N. Hovland Jr, S. G. Lehto, A. Gore, T. Juan, H. Deng, B. Han, L. Klionsky, et al.
The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation
J. Neurosci., March 28, 2007; 27(13): 3366 - 3374.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Klionsky, R. Tamir, B. Holzinger, X. Bi, J. Talvenheimo, H. Kim, F. Martin, J.-C. Louis, J. J. S. Treanor, and N. R. Gavva
A Polyclonal Antibody to the Prepore Loop of Transient Receptor Potential Vanilloid Type 1 Blocks Channel Activation
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 192 - 198.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. M. Johnson, E. M. Garrett, R. Rutter, T. P. Bonnert, Y.-D. Gao, R. E. Middleton, and K. G. Sutton
Functional Mapping of the Transient Receptor Potential Vanilloid 1 Intracellular Binding Site
Mol. Pharmacol., September 1, 2006; 70(3): 1005 - 1012.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics